Schizophrenia is a debilitating mental illness which involves three groups of symptoms, ie,
positive, negative and cognitive, and has major public health implications. According to …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

Second-generation antipsychotics (SGAs) are the cornerstone of treatment for schizophrenia
because of their high clinical efficacy. However, SGA treatment is associated with severe …

Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor
symptoms. Psychosis is a common feature of Parkinson's disease. Parkinson's disease …

Schizophrenia is a devastating illness that affects up to 1% of the population; it is
characterized by a combination of positive symptoms, negative symptoms, and cognitive …

Biological studies of bipolar disorder initially focused on the mechanism of action for
antidepressants and antipsychotic drugs, and the roles of monoamines (eg, serotonin …

Mounting evidence suggests that function and connectivity of the striatum is disrupted in
schizophrenia,,,–. We have developed a new hypothesis-driven neuroimaging biomarker for …

Antipsychotics represent the mainstay of schizophrenia pharmacological therapy, and their
role has been expanded in the last years to mood disorders treatment. Although introduced …

First seen as a fat-storage tissue, the adipose tissue is considered as a critical player in the
endocrine system. Precisely, adipose tissue can produce an array of bioactive factors …

Schizophrenia (SZ) has long been associated with a variety of cognitive deficits, including
reduced cognitive flexibility. More recent findings, however, point to tremendous inter …